The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of chronic obstructive pulmonary disease. The objective of the study was to evaluate the relative bioavailability, including the inter-subject variability, of a conventional immed...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Bruce E., Smart, Kevin, Mistry, Sunil, Ambery, Claire L., Bloomer, Jackie C., Connolly, Paul, Sanderson, Dominic, Shreeves, Trevor, Smith, Rachel, Lazaar, Aili L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142138/
https://www.ncbi.nlm.nih.gov/pubmed/24504700
http://dx.doi.org/10.1007/s13318-014-0179-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142138/
https://www.ncbi.nlm.nih.gov/pubmed/24504700
http://dx.doi.org/10.1007/s13318-014-0179-8

Ejemplares similares